Navigation Links
Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
Date:10/21/2008

LAUSANNE, Switzerland, October 21 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, announced today that the first healthy elderly subjects have been randomised in a clinical bioequivalence bridging study, conducted in the United States under IND (Investigational New Drug).

This study aims to compare the tolerability, safety and pharmacokinetic profiles of a single dose of two different Debio 9902 tablet formulations in healthy elderly subjects. This open label, randomized, crossover bioequivalence bridging study seeks to compare a new tablet formulation with the one used in the Phase IIb BRAINz trial (Better Recollection for Alzheimer's patients with the ImplaNt of ZT-1), which has now completed patient enrolment.

"Our primary objective is to provide a safe, comfortable and effective treatment for Alzheimer patients and the initiation of this bioequivalence trial brings us one step closer to our goal," said Kamel Besseghir, CEO of Debiopharm S.A. "Indeed, prior to receiving the Debio 9902 SR monthly implant, patients will receive the oral tablet formulation during a run-in period. The new tablet formulation will provide enhanced stability necessary to meet market requirements."

About Debio 9902 SR (ZT-1)

Debio 9902 SR is a novel acetylcholinesterase (AChE) inhibitor, administered monthly. It is transformed non-enzymatically into its active compound, huperzine A (hup A). Hup A has been used in China for centuries to treat distinct disorders such as memory loss, schizophrenia and hypertension, and is widely used in North America and Europe as a food additive to enhance cognition and neuroprotection. In addition to the inhibition of acetylcholinesterase by Debio 9902 SR, its potential neuroprotective effects as an N-methyl-D-aspartate receptor antagonist position this product as a third generation treatment for Alzheimer's disease.

About Alzheimer's Disease

AD is a progressive brain disorder that gradually destroys a person's memory and ability to learn, reason, make judgments, communicate and carry out daily activities. AD is characterised by the progressive destruction of brain cells leading to a decline in mental function and eventually, Alzheimer patients need complete care.

Current estimates show that approximately four million people suffer from AD in the US and 15 million worldwide. Most available treatments produce an increase of the acetylcholine levels by inhibiting AChE, the enzyme responsible for its breakdown. Currently used therapies have significant side-effects which can occur with a frequency of up to 50% for nausea for instance. These treatments generally require complicated titration schemes in order to minimise these cholinergic side-effects, which is a challenge when dealing with memory deficient patients.

An AChE inhibitor with a better tolerance profile than existing treatments and with an easierdosing schedule could improve patient compliance and therefore optimise the patient's treatment.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. It develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.65 billion in 2007.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com.

Debiopharm S.A. Contacts Additional Media Contacts In London

Maurice Wagner Maitland

Director Corporate Affairs & Brian Hudspith

Communications Tel: +44(0)20-7379-5151

Tel.: +41(0)21-321-01-11 bhudspith@maitland.co.uk

Fax: +41(0)21-321-01-69

mwagner@debiopharm.com

Jo-Anne Lutjens In New York

Communications Manager Russo Partners, LLC

Tel.: +41(0)79-370-27-15 Wendy Lau

Fax: +41(0)21-321-01-69 Tel: +1-212-845-4272

jalutjens@debiopharm.com Fax: +1-212-845-4260

wendy.lau@russopartnersllc.com


'/>"/>
SOURCE The Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
2. Multi-Centre European Clinical Trial Shows Advanced Dysplasia and Early Cancer of Esophagus Cured With Combined Endoscopic Resection and Radiofrequency Ablation With HALO Ablation System
3. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. First Town Hall Meeting on Inequities in Clinical Trials to Take Place at the Harlem Hospital Center on October 20
6. Perceptive Informatics Improves Clinical Trial Management With Enhanced TrialWorks(R) Solution
7. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
8. Surveyed Oncologists Say That the Most Promising Targeted Therapy in Adjuvant Clinical Trials is Avastin for the Treatment of Early-Stage Colorectal Cancer
9. Paratek to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
10. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
11. Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016  Syneron Medical Ltd. ... device company, announced today that William Griffing ... America, is scheduled to participate in the Leerink ... on February 11, 2016 in New ... institutional investors to meet with the Mr. Griffing ...
(Date:2/5/2016)... 5, 2016 ... the "Global Musculoskeletal Partnering 2010-2016: Deal ... to their offering. --> ... the "Global Musculoskeletal Partnering 2010-2016: Deal ... to their offering. --> ...
(Date:2/5/2016)... , Feb. 5, 2016  Zimmer Biomet Holdings, ... of the previously announced underwritten secondary offering of 11,027,558 ... stockholders, consisting of affiliates of Blackstone and Goldman Sachs. ... an initial price of $96.45 per share. The selling ... offering.  Neither Zimmer Biomet nor any of its directors, ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Brenntag Specialties, Inc.(BSI) , ... Food & Beverage and Dietary Supplement market segments across the ... USA geographies east of the Rocky Mountains since 2012. Consistent performance in ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... LA, celebrates the beginning of a new charity campaign. As part of their ... Special Advocates (CASA). In the belief that children deserve a voice, and in ...
(Date:2/8/2016)... ... 2016 , ... A man who has struggled to quit smoking, a man who has struggled ... to find solutions to his problems – and he did. Now Nabat, a serial entrepreneur ... introduce his breakthrough inventions to the world and better people's lives. His own experience with ...
(Date:2/8/2016)... ... ... If you are feeling that your clothes are a tad snug, the ... Center for Disease Control and Prevention (CDC), 34.9% of U.S. adult women are overweight. ... some of the leading causes of preventable death. February is heart health month ...
(Date:2/8/2016)... Hilton Head Island, SC (PRWEB) , ... February 08, 2016 , ... ... Head and surrounding areas with a vital new community enrichment program, has teamed up ... to local women and children suffering from intimate abuse. To support all those victimized ...
Breaking Medicine News(10 mins):